Results 71 to 80 of about 249,886 (308)

Failure of primary immunosuppressive agents in uveitis

Indian Journal of Ophthalmology
Purpose: This retrospective study aimed to evaluate the effectiveness of various immunomodulatory therapy (IMT) regimens in managing non-infectious uveitis (NIU) and to identify optimal treatment strategies for refractory cases.
Ankush Kawali, Sara Rizvi, Sai Bhakti Mishra, Padmamalini Mahendradas, Rohit Shetty   +4 more
doaj   +1 more source

Advisable including glucosaminylmuramyldipeptide in Helicobacter pylori therapy: experience of ten-year investigation

RUDN Journal of Medicine, 2020
Helicobacter pylori infection is a common bacterial infection in humans and is associated with peptic ulcer disease and chronic gastritis. The presence of natural resistance to some antibiotics in bacteria, as well as the appearance of primary and ...
M. R Konorev, S. V Guryanova, E. N Tyshevich, R. A Pavlyukov, O. Yu Borisova   +4 more
doaj   +1 more source

Regulatory immune cells in transplantation [PDF]

, 2012
Immune regulation is fundamental to any immune response to ensure that it is appropriate for the perceived threat to the host. Following cell and organ transplantation, it is essential to control the innate immune response triggered by the injured ...
Bushell, Andrew, Hester, Joanna, Wood, Kathryn J   +2 more
core   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

PD-L1+ neutrophils mediate immune regulation of CD8+ T cells in halo nevi

Frontiers in Immunology
BackgroundHalo nevi are clinically common and are characterized by a circle of leukoderma around the central melanocytic nevus. Studies have shown that the pathogenesis of halo nevi is similar to that of vitiligo and is associated with the role of CD8⁺ T
Yixuan Zhang, Yingying Xu, Wenjun Cui, Haoyang Wang, Min Li, Lu Liu   +5 more
doaj   +1 more source

A case report of late‐onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review

Brain and Behavior, 2021
Background and aims Interferon beta (IFNβ) is a well‐established first‐line therapy for relapsing–remitting multiple sclerosis (RRMS) patients and remains the most widely prescribed agent.
Mosè Parisi, Alessia Manni, Francesca Caputo, Maria Trojano, Damiano Paolicelli   +4 more
doaj   +1 more source

Immunotherapy of lung cancer: An update [PDF]

, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Aman MJ, Anthony HM, Atanackovic D, Bast RC, Bermers AJA, Carbone FR, Chan B, Cohen MH, Dickler M, Dranoff G, Dudley ME, Faradji A, Gotoh K, Grant SC, Kimura H, Kimura Y, Korkolopoulou P, Kradin RL, Krug LM, Krug LM, Liu M, Ma J, Marshall JL, Melioli G, Millar JW, Nemunaitis J, Nikitina E, O'Brien ME, Palmer M, Raez LE, Ratto GB, Salgia R, Smith A, Sterman D, Swisher S, Villalona-Calero MA, Yano T   +36 more
core   +1 more source

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein, Maximilian Mönch, Meret Herdick, Frauke Stascheit, Sarah Hoffmann, Hannah Preßler, Philipp Mergenthaler, Carla Dusemund, Paolo Doksani, Haoqi Sun, Pushpa Narayanaswami, Andreas Meisel, Lea Gerischer, Sophie Lehnerer   +13 more
wiley   +1 more source

Biological therapy in the treatment of melanoma [PDF]

, 2018
Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable ...
Benea, Vasile, Georgescu, Simona Roxana, Ghita, Ela, Ioghen, Mihaela Roxana, Ion, Alexandra-Florentina, Mitran, Cristina-Iulia, Mitran, Madalina-Irina, Sarbu, Maria Isabela, Tampa, Mircea   +8 more
core   +3 more sources

Immune‐Driven Expression in Inclusion Body Myositis With T‐Cell Large Granular Lymphocytic Leukemia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives T‐cell large granular lymphocytic leukemia (T‐LGLL), reported in up to 58% of inclusion body myositis (IBM) patients, is a rare leukemia of cytotoxic or less commonly helper T cells. The range of myopathies in T‐LGLL and the impact of coexisting T‐LGLL in IBM are not well understood. Our objectives are to investigate the spectrum of
Pannathat Soontrapa, Iago Pinal‐Fernandez, Pritikanta Paul, Michael P. Skolka, Margherita Milone, Min Shi, Mithun V. Shah, Maria Casal‐Dominguez, Katherine Pak, Andrew L. Mammen, Teerin Liewluck   +10 more
wiley   +1 more source